NCT02862743 (MELCIRC) is a NA clinical trial of patients with metastatic melanoma in Metastatic Melanoma, sponsored by CHU de Reims.

Who is sponsoring NCT02862743?

NCT02862743 is sponsored by CHU de Reims.

What drugs are being tested in NCT02862743?

Interventions in NCT02862743: patients with metastatic melanoma.

What condition does NCT02862743 study?

NCT02862743 studies Metastatic Melanoma.

Is NCT02862743 still recruiting?

NCT02862743 is currently completed. Last updated 21 January 2026.

Last reviewed 2026-01-21 · How we verify

NCT02862743: MELCIRC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Molecular Characterization of Advanced Stage Melanoma by Blood Sampling

Completed NA Last updated 21 January 2026

What this trial tests

NA trial testing patients with metastatic melanoma in Metastatic Melanoma in 50 participants. Completed in 31 December 2019.

Timeline

14 January 2016

Primary endpoint
31 December 2019

31 December 2019

Quick facts

Lead sponsor	CHU de Reims
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	50
Start date	14 January 2016
Primary completion	31 December 2019
Estimated completion	31 December 2019
Sites	1 location across France

Drugs / interventions tested

patients with metastatic melanoma

Conditions studied

Metastatic Melanoma — all drugs for Metastatic Melanoma →

Sponsor

CHU de Reims — full company profile →

Who can join

18 and older, any sex, with Metastatic Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Analysis of somatic mutations in tumors is currently indicated for daily practice in all metastatic melanoma. Actually, this research is limited to the mutation of three biomarkers validated by the l'Institut National du CAncer (INCA): BRAF, NRAS and CKIT. Moreover, in some cases it requires invasive biopsies. In this context, molecular characterization of a tumor material flowing (circulating tumor DNA and / or circulating tumor cells) could afford to benefit patients in the best conditions of current targeted therapies and future.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers.
Castellani G, Buccarelli M, Arasi MB, Rossi S, et al · · 2023 · cited 95× · PMID 37627054 · DOI 10.3390/cancers15164026
Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response.
Valenti F, Falcone I, Ungania S, Desiderio F, et al · · 2021 · cited 32× · PMID 33917181 · DOI 10.3390/ijms22083837
Liquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring.
Kamińska P, Buszka K, Zabel M, Nowicki M, et al · · 2021 · cited 23× · PMID 34575876 · DOI 10.3390/ijms22189714

Verify or expand the search:

Other recruiting trials for Metastatic Melanoma

Currently open trials in the same condition.

NCT06066138 — A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing · Phase 1 · recruiting
NCT07237100 — Mirdametinib in Patients With Advanced NF1-mutant Melanoma · Phase 2 · recruiting
NCT07086105 — A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma · Phase 1 · recruiting
NCT07112170 — Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma · NA · recruiting
NCT06488365 — In Vivo Liquid Biopsy of Melanoma (Cytophone) · NA · recruiting

Other CHU de Reims trials

Trials by the same sponsor.

NCT06955767 — Measurement of MMP-14 Protein, a Potential New Marker for Colorectal Cancer Detection, in Plasma Vesicles Named Exosomes · NA · recruiting
NCT07163338 — Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (IS) · NA · recruiting
NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
NCT06782997 — Performance of the Electroretinogram, Performed and Interpreted by an Advanced Practice Nurse, in the Screening for Diab · recruiting
NCT07016035 — Translation and Validation of the French mPCOSQ (mPCOSQ-F). · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02862743 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CHU de Reims
Last refreshed: 21 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02862743.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing